Sanofi (SAN FP) Japan announced on the 21st that it would postpone the launch of its high-dose influenza vaccine for the elderly, "Efluerda.", reports Nikkei

The postponement of Sanofi's high-dose influenza vaccine launch in Japan potentially signals delays in critical product rollouts, which could affect market perceptions of Sanofi's operational efficiency.

Newsquawk StaffPublished 21 Jul 2026, 11:24 UTCOn the live feed at 11:04 UTC — 6 more headlines followed before this page went public

Newsquawk headlinesUTC

11:10

Reform UK Leader Farage is to demand Andy Burnham call a general election and say he has no mandate to govern Britain, reports The Telegraph

11:09

Fars posts satellite images of the destruction of the US military's reconnaissance balloon equipment tent in Erbil, Iraq

11:04

Sanofi (SAN FP) Japan announced on the 21st that it would postpone the launch of its high-dose influenza vaccine for the elderly, "Efluerda.", reports Nikkei

11:01

Medtronic (MDT) unveils touch surgery aide real-time AI platform for robotic surgery

11:01

Intel (INTC) integrates REM technology into select Stellantis (STLAM IM/STLAP FP) vehicles from 2027

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

It was planned to be included in the routine vaccination schedule for those aged 75 and over from October 1st, but its introduction this fall has been postponed.
Initially, a launch around fall was anticipated. Sanofi Japan explained that "establishing and verifying some manufacturing processes at our domestic contract manufacturer is taking longer than expected," adding that "this will not affect its effectiveness or safety."
There will be no impact on Efluerda supplied outside of Japan. Efluerda is an influenza preventative vaccine approved in Japan for those aged 60 and over in 2024.

Context

While the company assures that this will not affect the vaccine's effectiveness or safety, the timing could impact sales forecasts and investor sentiment in the short term. Watch how this might influence sentiment toward the broader pharmaceutical sector, particularly in Asia.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.